TRexBio (TRXB) said Thursday it priced its initial public offering of roughly 8.3 million common shares at $14 per share.

The company expects to raise roughly $116.7 million in gross proceeds from the sale, and its stock is expected to begin trading Friday on the Nasdaq Global Select Market (NDAQ) under the ticker symbol TRXB, the company said.

Underwriters have a 30-day option to buy up to an additional 1.25 million shares, and the transaction is expected to close Oct. 13, pending customary conditions, TRexBio said.